Citigroup Maintains Buy on Unity Biotechnology, Raises Price Target to $6
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Yigal Nochomovitz maintains a Buy rating on Unity Biotechnology (NASDAQ:UBX) and raises the price target from $5 to $6.
May 26, 2023 | 10:41 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Citigroup analyst Yigal Nochomovitz maintains a Buy rating on Unity Biotechnology and raises the price target from $5 to $6.
Citigroup's maintained Buy rating and increased price target for Unity Biotechnology (UBX) indicate a positive outlook for the company's stock. This news is likely to have a positive impact on UBX's stock price in the short term as it reflects the analyst's confidence in the company's potential growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100